Eric Ko to Combined Modality Therapy
This is a "connection" page, showing publications Eric Ko has written about Combined Modality Therapy.
Connection Strength
0.936
-
Ko EC, Hanna GJ. Immunotherapy for head and neck cancer: where do we go from here? Immunotherapy. 2023 12; 15(18):1497-1500.
Score: 0.206
-
Agrawal V, Benjamin KT, Ko EC. Radiotherapy and Immunotherapy Combinations for Lung Cancer. Curr Oncol Rep. 2020 11 19; 23(1):4.
Score: 0.167
-
Ko EC, Formenti SC. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality. Int J Radiat Biol. 2019 07; 95(7):936-939.
Score: 0.151
-
Ko E. Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non-Small-Cell Lung Cancer. Oncology (Williston Park). 2018 09 15; 32(9):460-2.
Score: 0.144
-
Ko EC, Raben D, Formenti SC. The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 12 01; 24(23):5792-5806.
Score: 0.142
-
Ko EC, Liu JT, Stone NN, Stock RG. Association of early PSA failure time with increased distant metastasis and decreased survival in prostate brachytherapy patients. Radiother Oncol. 2014 Feb; 110(2):261-7.
Score: 0.103
-
Tong CC, Lau KH, Rivera M, Cannan D, Aguirre-Ghiso J, Sikora AG, Gupta V, Forsythe K, Ko EC, Misiukiewicz K, Gurudutt V, Teng MS, Packer SH, Genden EM, Kao J. Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy. Oncol Rep. 2012 May; 27(5):1580-6.
Score: 0.023